Drugs / GRAd-COV2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04528641 | Aug 2020 → May 2021 | COVID-19 | ReiThera Srl | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04791423 | Mar → Jun 2021 | COVID-19 | ReiThera Srl | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2022-09-27 | ReiThera Srl | Results GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomised placebo-controlled phase 2 trial (COVITAR) reithera.com ↗ |
| 2022-01-23 | ReiThera Srl | Results Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 reithera.com ↗
We show that our vaccine candidate, GRAd-COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies that neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, T helper (Th)1-dominated cellular response. |
| 2021-11-02 | ReiThera Srl | Results Positive Results from ReiThera’s Phase 1 Trial with COVID-19 Vaccine Candidate GRAd-COV2 Published in Science Translational Medicine reithera.com ↗
Four weeks after vaccination, seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants. |
| 2021-07-12 | ReiThera Srl | Results ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate reithera.com ↗
today announces the preliminary safety and immunogenicity data from the Phase 2 clinical “COVITAR” trial with GRAd-COV2, its novel COVID-19 vaccine candidate. |
| 2020-11-30 | ReiThera Srl | Results Vaccino anti Covid ReiThera, bene la prima fase sperimentata a Castel Romano reithera.com ↗
La stessa azienda annuncia che il suo candidato vaccino GRAd-COV2 COVID-19 è ben tollerato e induce risposta immunitaria nei soggetti sani di età compresa tra i 18 e i 55 anni. |
| 2020-11-24 | ReiThera Srl | Results ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18-55 Years Phase 1 Trial to Advance into Elderly Subjects Aged 65-85 Years reithera.com ↗
Preliminary results from this cohort , which was divided into three study arms of 15 subjects, have shown that GR A d-COV2 was well-tolerated and generated spike-binding antibod ies and T-cell responses at all three doses tested. |
| 2020-08-03 | ReiThera Srl | Regulatory COVID-19 – AIFA autorizza la sperimentazione di fase I del vaccino ReiThera in Italia reithera.com ↗
L’Agenzia Italiana del Farmaco ha autorizzato la sperimentazione di fase I sul vaccino anti-COVID-19 prodotto dall’azienda bio-tecnologica italiana ReiThera. |
| 2020-08-03 | ReiThera Srl | Regulatory Coronavirus, la sfida del vaccino tutto italiano: arruolati 90 volontari reithera.com ↗
L’Agenzia del farmaco ha autorizzato la sperimentazione di fase I: GRAd-CoV2 è basato su un vettore adenovirale, come il vaccino sviluppato dall’Università di Oxford |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRAd-COV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04791423 ↗ |
| Modality | Vaccine | “gorilla adenovirus-vectored vaccine” PMID 33895322 ↗ Apr 2021 |
| Route | Intramuscular | “Single intramuscular administration.” NCT04528641 ↗ |